Search results
Results from the WOW.Com Content Network
Ondansetron, sold under the brand name Zofran among others, is a medication used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, migraines, or surgery. [8] It is also effective for treating gastroenteritis. [9] [10] It can be given orally (by mouth), intramuscularly (injection into a muscle), or intravenously ...
The first ODT form of a drug to get approval from the U.S. Food and Drug Administration (FDA) was a Zydis ODT formation of Claritin in December 1996. [19] It was followed by a Zydis ODT formulation of Klonopin ( clonazepam ) in December 1997, [ 20 ] and a Zydis ODT formulation of Maxalt ( rizatriptan ) in June 1998. [ 21 ]
Sublingual and buccal medication administration is a way of giving someone medicine orally (by mouth). Sublingual administration is when medication is placed under the tongue to be absorbed by the body. The word "sublingual" means "under the tongue." Buccal administration involves placement of the drug between the gums and the cheek.
Lozenge—effects a metred and patient-controlled-rate combination of sublingual, buccal, and oral administration, as with the Actiq fentanyl. Effervescent buccal or sublingual tablets—this method drives the drug through the mucous membranes much faster (this is the case in the stomach with carbonated or effervescent liquids as well) and is ...
5-HT 3 antagonists are most effective in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), especially that caused by highly emetogenic drugs such as cisplatin; when used for this purpose, they may be given alone or, more frequently, with a glucocorticoid, usually dexamethasone.
Enteral administration involves the esophagus, stomach, and small and large intestines (i.e., the gastrointestinal tract). Methods of administration include oral, sublingual (dissolving the drug under the tongue), and rectal. Parenteral administration is via a peripheral or central vein. [1]
Evaluating the systemic transmucosal drug delivery, the buccal mucosa is the preferred region as compared to the sublingual mucosa. Oral Thin Films (Oral Dissolvable Strips) address several of the disadvantages of tablets or capsules such as dysphagia or the inability to adjust dosing to patient parameters, often resulting to a lack of ...
Zydis technology was developed by R.P. Scherer Corporation (currently owned by Catalent Pharma Solutions) in 1986. [2] The technology's first commercial application was in August, 1993, when a new dosage form of Pepcidine from Merck & Co. was launched in Sweden.